Given ProQR Therapeutics' successful $63 million public offering and key collaborations focusing on its Axiomer™ RNA editing technology, I believe the stock is poised for significant growth. The recent uptick in investor interest reinforces my decision to purchase PRQR as it shows strong potential within the RNA therapy sector.